Eosinophil Deficiency Promotes Aberrant Repair and Adverse Remodeling Following Acute Myocardial Infarction.
BMD, bone marrow derived
IL, interleukin
MI, myocardial infarction
PBS, phosphate-buffered saline
STEMI
STEMI, ST-segment elevation myocardial infarction
WT, wild-type
eosinophil
mRNA, messenger RNA
qPCR, quantitative polymerase chain reaction
remodeling
Journal
JACC. Basic to translational science
ISSN: 2452-302X
Titre abrégé: JACC Basic Transl Sci
Pays: United States
ID NLM: 101677259
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
28
08
2019
revised:
12
05
2020
accepted:
12
05
2020
entrez:
8
8
2020
pubmed:
8
8
2020
medline:
8
8
2020
Statut:
epublish
Résumé
In ST-segment elevation myocardial infarction of both patients and mice, there was a decline in blood eosinophil count, with activated eosinophils recruited to the infarct zone. Eosinophil deficiency resulted in attenuated anti-inflammatory macrophage polarization, enhanced myocardial inflammation, increased scar size, and deterioration of myocardial structure and function. Adverse cardiac remodeling in the setting of eosinophil deficiency was prevented by interleukin-4 therapy.
Identifiants
pubmed: 32760855
doi: 10.1016/j.jacbts.2020.05.005
pii: S2452-302X(20)30224-2
pmc: PMC7393409
doi:
Types de publication
Journal Article
Langues
eng
Pagination
665-681Subventions
Organisme : British Heart Foundation
ID : RG/16/10/32375
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K01207X/1
Pays : United Kingdom
Organisme : British Heart Foundation
ID : PG/16/58/32275
Pays : United Kingdom
Organisme : British Heart Foundation
ID : CH/09/002/26360
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K01207X/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M011542/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/K013386/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
© 2020 The Authors.
Références
Circ Res. 2008 Feb 1;102(2):257-64
pubmed: 18007026
Eur J Immunol. 2016 Dec;46(12):2749-2760
pubmed: 27621211
J Exp Med. 2002 Jun 3;195(11):1387-95
pubmed: 12045237
J Am Coll Cardiol. 2015 May 19;65(19):2057-66
pubmed: 25975467
J Invest Dermatol. 1999 Oct;113(4):617-21
pubmed: 10504450
J Am Coll Cardiol. 2010 Apr 13;55(15):1629-38
pubmed: 20378083
Eur Heart J. 2012 Oct;33(20):2551-67
pubmed: 22922414
Thromb Res. 2012 Oct;130(4):607-11
pubmed: 22771073
Clin Exp Immunol. 2019 Oct;198(1):83-93
pubmed: 31119724
Basic Res Cardiol. 2018 Jun 4;113(4):26
pubmed: 29868933
Tex Heart Inst J. 2017 Jun 1;44(3):176-188
pubmed: 28761398
J Exp Med. 2017 Apr 3;214(4):943-957
pubmed: 28302646
Immunity. 2015 Jul 21;43(1):187-99
pubmed: 26200014
Proc Natl Acad Sci U S A. 2013 Jun 11;110(24):9914-9
pubmed: 23716700
J Clin Invest. 1975 Oct;56(4):870-9
pubmed: 1099120
J Clin Invest. 2016 Jun 1;126(6):2151-66
pubmed: 27140396
Atherosclerosis. 2017 Aug;263:82-91
pubmed: 28623741
J Exp Med. 2007 Nov 26;204(12):3037-47
pubmed: 18025128
Biochim Biophys Acta. 2005 Jun 30;1741(1-2):95-102
pubmed: 15955452
J Clin Invest. 1980 Jun;65(6):1265-71
pubmed: 7410543
Immunol Rev. 2014 Nov;262(1):113-33
pubmed: 25319331
J Atheroscler Thromb. 2017 Aug 1;24(8):827-840
pubmed: 27904028
Endocrinology. 2016 Jan;157(1):346-57
pubmed: 26465199
Cell. 2013 Apr 11;153(2):376-88
pubmed: 23582327
J Bone Miner Res. 2005 Jan;20(1):81-7
pubmed: 15619673
J Allergy Clin Immunol. 2012 Sep;130(3):572-84
pubmed: 22935586
Circ Res. 2014 May 9;114(10):1611-22
pubmed: 24625784
Immunity. 2019 Jul 16;51(1):131-140.e5
pubmed: 31315031
Nat Med. 2018 Aug;24(8):1234-1245
pubmed: 29892064
Science. 2011 Apr 8;332(6026):243-7
pubmed: 21436399
J Mol Cell Cardiol. 2019 Apr;129:92-104
pubmed: 30771308
Equine Vet J. 2017 Sep;49(5):609-613
pubmed: 27859600
J Immunol. 1999 Jun 15;162(12):7302-8
pubmed: 10358179
Hum Pathol. 1985 Jun;16(6):562-8
pubmed: 3997134
Circulation. 2018 Feb 27;137(9):948-960
pubmed: 29167227
Sci Rep. 2017 Jul 31;7(1):6877
pubmed: 28761077